The Glucagon-Like Peptide-1 Receptor—or Not?
The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Glucagon-like peptide-1 (GLP-1)-based diabetes therapy is increasingly used in the treatment of type 2 diabetes. Two GLP-1 analogs, liraglutide and exenatide, have been approved for clinical use and act as agonists of the GLP-1 receptor (GLP-1R), a member of the glucagon receptor family of G protein-coupled receptors (GPCRs) (1). Also, the clinical effect of Di-Peptidyl Peptidase-4 (DPP-4) inhibitors is at least partially resulting from an increased level of active GLP-1 (2). The unambiguous identification of GLP-1R-expressing cells in humans and animal species constitutes critically important knowledge for fully understanding the pharmacological effects of GLP-1R agonists, both those associated with the documented clinical benefits as well as any potential undesired effects of treatment. The GLP-1R was cloned in 1992 (3). Preceding that, the receptor was identified in numerous cell types and organs, most obviously the pancreatic β-cell but also in rat lung and brain by studies using either ligand binding or functional assays (4, 5). After the receptor was cloned, RT-PCR and in situ hybridization were used to report tissue distribution, and the receptor was located in the intestine, stomach, kidney, lungs, heart, and brain (6, 7). Later studies have used Western blotting and immunohistochemistry to identify the exact cellular localization of the receptor. Using such techniques, the receptor has been identified in mouse cardiomyocytes and smooth muscle cells in the heart, and in porcine tubular cells in the kidney (8, 9). Human GLP-1R expression has been mapped by in situ ligand binding across a wide range of both normal and tumor tissues (10). In this issue of Endocrinology, Panjwani et al. (11) reports new knowledge about the mechanism of action of GLP-1 analogs in atherosclerosis and hepatic steatosis and challenges some GLP-1R expression data in macrophages and hepatocytes that have previously been published. When Panjwani et al. (11) could not identify GLP-1R mRNA on macrophages or isolated hepatocytes despite previous reports of such localization, they did a careful Western blotting characterization of three commercially available polyclonal antibodies (PAbs) against the GLP-1R that are commonly used for Western blotting. They used mouse wild-type lung tissue that has a very high expression of GLP-1R as a positive control and lung tissue from GLP-1R−/− mice as a negative control. They also employed a very thorough procedure with immunoprecipitation in an attempt to increase the sensitivity of the analysis but found no GLP-1R-specific expression. The authors conclude that multiple commercially available GLP-1R antibodies do not detect authentic GLP-1R protein, even using optimally enhanced methods. This technical difficulty at first glance seems to have little bearing on aspects of GLP-1 biology unrelated to the scope of the article; however, on further consideration, it brings into focus a potentially serious problem with the validity of any GLP-1R expression data generated through the use of antibodies. Adding to the complexity, for some GLP-1R-containing organs, markedly different GLP-1R expression patterns have been reported between human and rodent species (10, 12). Rodent thyroid C-cells express much higher levels of GLP-1R than primates (10, 12), and there may be an important species difference, where the GLP-1R in the rodent thyroid is important for the high bone turnover in those species but less important in humans (13, 14). In the lung, the number of GLP-1R-expressing cells and the receptor density is much lower in humans than in rodent species (10), but the role and importance of lung GLP-1R is relatively unexplored. Three different histological techniques are available for mapping the identity of cells expressing a receptor like the GLP-1R. First, in situ hybridization is the method of choice for detecting mRNA in tissues; however, for a low-abundance target like the GLP-1R, only methods depending on the use of radioactively labeled probes will provide the required sensitivity, and unfortunately, the final autoradiography step severely limits the resolution of the output signal. A similar problem exists for in situ ligand binding (ISLB) with radioactively labeled ligand, although this method has been highly useful for detecting a functional GLP-1R in cell types that can be identified despite the limited resolution (12, 15). The third method, and the one most often employed to map GLP-1R localization by researchers in the field, is immunohistochemistry (IHC) with anti-GLP-1R antibodies. IHC offers the best resolution and allows unambiguous cell identification; however, for GPCRs, it is notoriously difficult, and a high focus on validation of antibodies and protocols is imperative. Further adding to the difficulty of generating reliable GPCR protein expression data, the normal physiological cell density of many GPCRs can be very low. In one issue of the journal Naunyn-Schmiedeberg’s Archives
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The limited specificity of many antibodies against mouse and human GLP-1R, combined with the challenges of detecting the receptor at low abundance, has been well documented (37, 39, 40).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [39]
In the citing paper
“GLP-1 acts through a class 2 member of the G-coupled protein C receptor family seven-transmembrane receptor (GLP-1R) (8), which is mainly expressed in pancreatic islets, the brain, and the gastrointestinal (GI) tract (9–12), and less prominently in the kidney and eyes (11–13).”
From The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications (2026) · cites this paper as [11]
In the citing paper
“However, these studies were later refuted, as incompletely validated GLP-1 receptor antisera were used (81).”
From Safety of Semaglutide (2021) · cites this paper as [81]
Citations
Cites
Ban, K., Noyan-Ashraf, M. H., Hoefer, J., Bolz, S.-S., Drucker, D. J., & Husain, M. (2008) · Circulation · doi:10.1161/circulationaha.107.739938 · Cited by 1,057 · cited 1×
“Using such techniques, the receptor has been identified in mouse cardiomyocytes and smooth muscle cells in the heart, and in porcine tubular cells in the kidney (8, 9).”
BackgroundThorens, B. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.18.8641 · Cited by 906
Bjerre Knudsen, L., Madsen, L. W., Andersen, S., Almholt, K., de Boer, A. S., Drucker, D. J., Gotfredsen, C., Egerod, F. L., Hegelund, A. C., Jacobsen, H., et al. (2010) · Endocrinology · doi:10.1210/en.2009-1272 · Cited by 672
Self-citationTissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor
Bullock, B. P., Heller, R. S., & Habener, J. F. (1996) · Endocrinology · doi:10.1210/en.137.7.2968 · Cited by 618 · cited 1×
“the intestine, stomach, kidney, lungs, heart, and brain (6, 7).”
GLP-1 Receptor Expression in Human Tumors and Human Normal Tissues: Potential for In Vivo Targeting
Korner, M., Stockli, M., Waser, B., & Reubi, J. C. (2007) · Journal of Nuclear Medicine · doi:10.2967/jnumed.106.038679 · Cited by 477 · cited 4×
“Adding to the complexity, for some GLP-1R-containing organs, markedly different GLP-1R expression patterns have been reported between human and rodent species (10, 12).”
BackgroundInfluentialGöke, R., Larsen, P. J., Mikkelsen, J. D., & Sheikh, S. P. (1995) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.1995.tb00650.x · Cited by 474 · cited 1×
“A similar problem exists for in situ ligand binding (ISLB) with radioactively labeled ligand, although this method has been highly useful for detecting a functional GLP-1R in cell types that can be identified despite the limited resolution (12, 15).”
MethodCampos, R. V. (1994) · Endocrinology · doi:10.1210/en.134.5.2156 · Cited by 353
Panjwani, N., Mulvihill, E. E., Longuet, C., Yusta, B., Campbell, J. E., Brown, T. J., Streutker, C., Holland, D., Cao, X., Baggio, L. L., et al. (2013) · Endocrinology · doi:10.1210/en.2012-1937 · Cited by 346 · cited 2×
“(11) reports new knowledge about the mechanism of action of GLP-1 analogs in atherosclerosis and hepatic steatosis and challenges some GLP-1R expression data in”
BackgroundThe Murine Glucagon-Like Peptide-1 Receptor Is Essential for Control of Bone Resorption
Yamada, C., Yamada, Y., Tsukiyama, K., Yamada, K., Udagawa, N., Takahashi, N., Tanaka, K., Drucker, D. J., Seino, Y., & Inagaki, N. (2008) · Endocrinology · doi:10.1210/en.2007-1292 · Cited by 318
How reliable are G-protein-coupled receptor antibodies?
Michel, M. C., Wieland, T., & Tsujimoto, G. (2009) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/s00210-009-0395-y · Cited by 306
Cited by
Items 101–171 of 171
Sjøberg, K. A., Rattigan, S., Jeppesen, J. F., Lundsgaard, A., Holst, J. J., & Kiens, B. (2015) · The Journal of Physiology · doi:10.1113/jp270129 · Cited by 27
“However, the GLP-1 receptor appears to be less abundant in intact skeletal muscle in humans (Green et al. 2012), dogs (Sandhu et al. 1999), and rats (Green et al. 2008) and its direct effect on skeletal muscle glucose uptake is not fully elucidated (Pyke & Knudsen, 2013).”
BackgroundBangshaab, M., Cruz, A. G., Huynh, K. D., Knudsen, J. S., Arcanjo, D. D. R., Petersen, A. G., Rungby, J., Gejl, M., & Simonsen, U. (2018) · British Journal of Pharmacology · doi:10.1111/bph.14534 · Cited by 27
Katsuda, Y., Ohta, T., Shinohara, M., Tong, B., & Yamada, T. (2013) · Open Journal of Animal Sciences · doi:10.4236/ojas.2013.34050 · Cited by 27
Burghi, V., Fernández, N. C., Gándola, Y. B., Piazza, V. G., Quiroga, D. T., Mário, É. G., Braga, J. F., Bäder, M., Santos, R. A. S., Dominici, F. P., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0183278 · Cited by 26
Influence of GLP-1 on Myocardial Glucose Metabolism in Healthy Men during Normo- or Hypoglycemia
Gejl, M., Lerche, S. S., Mengel, A., Møller, N., Bibby, B. M., Smidt, K., Brock, B., Søndergaard, H. M., Bøtker, H. E., GJEDDE, A. H., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0083758 · Cited by 26
Expanded LUXendin Color Palette for GLP1R Detection and Visualization In Vitro and In Vivo
Ast, J., Novak, A. N., Podewin, T., Fine, N. H. F., Jones, B. J., Tomás, A., Birke, R., Roßmann, K., Mathes, B., Eichhorst, J., et al. (2022) · JACS Au · doi:10.1021/jacsau.2c00130 · Cited by 25
The GLP-1-mediated gut-kidney cross talk in humans: mechanistic insight
Hinrichs, G. R., Hovind, P. H., & Asmar, A. (2023) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00476.2023 · Cited by 23
Effects of incretin-based therapies on renal function
Tsimihodimos, V., & Elisaf, M. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.10.049 · Cited by 22
“All researchers agree that this kind of receptors is present in human kidney vasculature, whereas its presence in renal glomeruli and proximal tubular cells still remains a subject of debate (Crajoinas et al., 2011; Pyke and Knudsen, 2013; Schlatter et al., 2007).”
BackgroundFluorescent GLP1R/GIPR dual agonist probes reveal cell targets in the pancreas and brain
de Bray, A., Roberts, A. G., Armour, S. L., Tong, J., Huhn, C., Gatin‐Fraudet, B., Roßmann, K., Shilleh, A. H., Jiang, W., Burgos, N. S. F., et al. (2025) · Nature Metabolism · doi:10.1038/s42255-025-01342-6 · Cited by 21
“No approach to date provides information on GLP1Rs and GIPRs specifically accessed or bound by a dual agonist.”
Bremholm, L., Andersen, U. B., Hornum, M., Hilsted, L., Veedfald, S., Hartmann, B., & Holst, J. J. (2017) · Physiological Reports · doi:10.14814/phy2.13102 · Cited by 20
“The mapping of the GLP-1 receptor localization has been hampered by problems with inadequate specificity of the antibodies employed (Pyke and Knudsen 2013; Pyke et al. 2014; Ussher and Drucker 2014).”
BackgroundCardiovascular and hemodynamic effects of glucagon-like peptide-1
Goodwill, A. G., Mather, K. J., Conteh, A. M., Sassoon, D., Noblet, J. N., & Tune, J. D. (2014) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-014-9290-z · Cited by 19
Malbert, C.-H., Chauvin, A., Horowitz, M., & Jones, K. L. (2021) · Diabetes · doi:10.2337/db20-0361 · Cited by 18
Drug repositioning in thyroid cancer treatment: the intriguing case of anti-diabetic drugs
Greco, A., Coperchini, F., Croce, L., Magri, F., Teliti, M., & Rotondi, M. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1303844 · Cited by 18
“This caution is based only on data from rodent studies and is not unique for semaglutide amongst the GLP-1RA (Bjerre Knudsen et al., 2010; Pyke and Knudsen, 2013).”
BackgroundGLP-1 mimetic drugs and the risk of exocrine pancreatic disease: Cell and animal studies
Williams, J. A. (2015) · Pancreatology · doi:10.1016/j.pan.2015.11.008 · Cited by 18
Lehtonen, J., Schäffer, L., Rasch, M. G., Hecksher-Sørensen, J., & Ahnfelt-Rønne, J. (2015) · Islets · doi:10.1080/19382014.2015.1137415 · Cited by 17
Impact of glucagon-like peptide-1 on myocardial glucose metabolism revisited
Hansen, J., Brock, B., Bøtker, H. E., GJEDDE, A. H., Rungby, J., & Gejl, M. (2014) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-014-9286-8 · Cited by 16
Histological analysis of glucagon-like peptide-1 receptor expression in chicken pancreas
Watanabe, T., Nishimura, K., Hosaka, Y. Z., Shimosato, T., Yonekura, S., Suzuki, D., Takemoto, C., Monir, M. M., & Hiramatsu, K. (2014) · Cell and Tissue Research · doi:10.1007/s00441-014-1836-6 · Cited by 15
“…Shinshu University, Nagano 399-4598, Japan D. Suzuki Department of Musculoskeletal Biomechanics and Surgical Development, School of Medicine, Sapporo Medical University, Sapporo, Hokkaido 060-0061, Japan tissues including pancreatic islets (Pyke and Knudsen 2013; Tornehave et al. 2008).”
BackgroundMethodInfluentialReubi, J. C. (2014) · Endocrine · doi:10.1007/s12020-014-0320-0 · Cited by 15
“Otherwise, unnecessary repeats and reports of IHC experiments with no clear conclusion will be the consequence, as recently shown by examples in the field of receptors for somatostatin and GLP1 [1, 2, 12, 13].”
BackgroundReassessment of antibody-based detection of the murine T cell GLP-1 receptor
Wong, C. K., Yusta, B., Tong, J. C. L., Broichhagen, J., Hodson, D. J., & Drucker, D. J. (2025) · Cell Metabolism · doi:10.1016/j.cmet.2025.06.012 · Cited by 14
Incretins and bone: friend or foe?
Mabilleau, G. (2015) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2015.03.007 · Cited by 14
Validation of antibody-based tools for galanin research
Brunner, S. M., Koller, A., Stockinger, J., Sternberg, F., Leis, S., Ernst, F., Strasser, P., Brodowicz, B., Ebner, S., Holub, B. S., et al. (2018) · Peptides · doi:10.1016/j.peptides.2018.08.010 · Cited by 13
A Critical Evaluation of sst3 and sst5 Immunohistochemistry in Human Pituitary Adenomas
Körner, M., Waser, B., Christ, E., Beck, J., & Reubi, J. C. (2017) · Neuroendocrinology · doi:10.1159/000472563 · Cited by 12
Manell, E., Puuvuori, E., Svensson, A. C., Velikyan, I., Hulsart‐Billström, G., Hedenqvist, P., Holst, J. J., Jensen‐Waern, M., & Eriksson, O. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-002083 · Cited by 11
Glucagon-Like Peptide-1 Receptor Expression in Normal and Neoplastic Human Pancreatic Tissues
Molin, M. D., Kim, H., Blackford, A. L., Sharma, R. B., & Goggins, M. (2015) · Pancreas · doi:10.1097/mpa.0000000000000521 · Cited by 10
Gharib, S. A., Vemireddy, R., Castillo, J., Fountaine, B. S., Bammler, T. K., MacDonald, J. W., Hull, R. L., & Zraika, S. (2024) · Scientific Reports · doi:10.1038/s41598-024-76722-1 · Cited by 10
“Attempts to achieve reliable GLP-1R staining in sections from Cohort 1 were unsuccessful, likely due to the known challenges in detecting G protein-coupled receptors 60 , especially in autopsy samples.”
GLP-1 vasodilatation in humans with coronary artery disease is not adenosine mediated
Aetesam‐ur‐Rahman, M., Giblett, J. P., Khialani, B. V., Kyranis, S. J., Clarke, S. J., Zhao, T. X., Braganza, D. M., Clarke, S., West, N. E. J., Bennett, M. R., et al. (2021) · BMC Cardiovascular Disorders · doi:10.1186/s12872-021-02030-5 · Cited by 10
GLP-1 Provoked Severe Hypoglycemia in an Individual With Type 2 Diabetes and a Benign Insulinoma
Ruby, R. J., Armato, J., Pyke, C., & Peters, A. L. (2014) · Diabetes Care · doi:10.2337/dc14-0514 · Cited by 10
Self-citationTargeting Epicardial Fat in Obesity and Diabetes Pharmacotherapy
Iacobellis, G., Basilico, S., & Malavazos, A. E. (2022) · Handbook of experimental pharmacology · doi:10.1007/164_2021_577 · Cited by 8
Tajima, K., Shirakawa, J., Togashi, Y., Inoue, H., Sato, K., Orime, K., Ito, Y., Kaji, M., Sakamoto, E., Nakamura, A., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0064633 · Cited by 8
Pancreatic GLP-1r binding potential is reduced in insulin-resistant pigs
Malbert, C., Chauvin, A., Horowitz, M., & Jones, K. L. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001540 · Cited by 4
Starup‐Linde, J. (2014) · Journal of Diabetes & Metabolism · doi:10.4172/2155-6156.1000389 · Cited by 4
Myat, A., Arri, S. S., Bhatt, D. L., Gersh, B. J., Redwood, S. R., & Marber, M. S. (2015) · Cardiovascular Diabetology · doi:10.1186/s12933-015-0193-4 · Cited by 4
Zhang, L., & Thurber, G. M. (2017) · Springer eBooks · doi:10.1007/978-3-319-61401-4_8 · Cited by 4
Williams, J. A. (2014) · doi:10.3998/panc.2014.7 · Cited by 4
State of the Art Review: Glucagon-Like Peptide-1 in Obesity-Related Asthma
Gomez, D. R., Swartzman, I., Linderholm, A., Cummings, B. P., Zeki, A. A., Sundar, K. M., & Kenyon, N. J. (2025) · Lung · doi:10.1007/s00408-025-00861-z · Cited by 3
“…difference in detection methodologies, tissue preparation techniques, and the specificity and reliability of antibodies to bind GLP-1 receptor protein in immunohistochemical analyses, highlighting the need for more standardized and sensitive approaches and better reporting in the literature [76].”
Exendin-4 Protects Neural Progenitor Cells from Glucolipoapoptosis
Mansouri, S. (2014) · Journal of Diabetes & Metabolism · doi:10.4172/2155-6156.1000409 · Cited by 3
Automated ISH for Validated Histological Mapping of Lowly Expressed Genes
Pyke, C. (2020) · Methods in molecular biology · doi:10.1007/978-1-0716-0623-0_14 · Cited by 3
Self-citationGLP-1 and GIP in Type 1 Diabetes Therapy: A Time for Reappraisal?
Piras, G., Brasili, S., Demontis, D., Sala, L. D., Cocchiara, F., Maggi, D. C., & Arecco, A. (2026) · Diabetology · doi:10.3390/diabetology7030050 · Cited by 2
Neuropeptide Y Y 5 receptor localization in mouse central nervous system
Murase, S.-I., Shiiya, T., & Higuchi, H. (2016) · Brain Research · doi:10.1016/j.brainres.2016.10.026 · Cited by 2
“As the absence of immunohistochemical reaction in tissues of knockout animals of the corresponding antigen is regarded as the “hard specificity criterion” (Gore, 2013; Pradidarcheep et al., 2009; Pyke and Knudsen, 2013), the preabsorbed antibody was used for whole experiments in this study.”
Impact of incretin-related agents on endothelial cell function
Nomoto, H., Miyoshi, H., Nakamura, A., Atsumi, T., Manda, N., Kurihara, Y., Aoki, S., & on behalf of SAIS Study Group (2017) · Clinical Trials in Degenerative Diseases · doi:10.4103/2542-3975.202726 · Cited by 2
Targeting the Epicardial Adipose Tissue
Iacobellis, G. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-40570-0_15 · Cited by 1
Incretin-based therapies for the failing heart
Ussher, J. R., & Campbell, J. E. (2016) · Cardiovascular Endocrinology · doi:10.1097/xce.0000000000000086 · Cited by 1
Reubi, J. C. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.197582 · Cited by 1
Molecular Imaging Agent Design for Quantifying Beta Cell Mass in Type 1 Diabetes
Zhang, L. (2017) · Deep Blue (University of Michigan) · Cited by 1
Arterial responses to infusion of glucagon-like peptide-1 in humans: A randomized trial study
Ghanizada, H., Christensen, R. H., Al‐Karagholi, M. A., Elbahi, F. A., Coskun, H., & Ashina, M. (2022) · Peptides · doi:10.1016/j.peptides.2022.170736 · Cited by 1
Precision medicine: recent advances, current challenges and future perspectives
(2024) · Frontiers research topics · doi:10.3389/978-2-8325-5042-7 · Cited by 1
GLP-1 receptor – Do we really know what we’re looking at?
Homolak, J., Perhoč, A. B., Knezović, A., Barilar, J. O., & Šalković‐Petrišić, M. (2021) · Acta Histochemica · doi:10.1016/j.acthis.2021.151732 · Cited by 1
Jun, L. S., Showalter, A. D., Ali, N., Dai, F. F., Ma, W., Coşkun, T., FICORILLI, J. V., Wheeler, M. B., Michael, M. D., & Sloop, K. W. (2015) · PLoS ONE · doi:10.1371/journal.pone.0132875 · Cited by 1
Glucagon-like peptide-1 in nonalcoholic steatohepatitis
Armstrong, M. J. (2014) · University of Birmingham Institutional Research Archive (University of Birmingham)
Andréasson, S. (2015) · Epsilon Archive for Student Projects (Swedish University of Agricultural Sciences)
Role of the Glucagon and Glucagon-like Peptides in Pancreatic Beta Cell and Cardiovascular Function
Ali, S. (2014) · TSpace (University of Toronto)
Brial, F. (2014) · Knowledge UdeS (Institutional Deposit of the University of Sherbrooke)
Jandova, T. (2017) · Nottingham ePrints (University of Nottingham)
Molecular imaging and immunotherapy in atherosclerotic cardiovascular disease
Ståhle, M. R. (2020) · UTUPub (University of Turku)
Refinement of porcine models in diabetes and transplantation research
Manell, E. (2020) · Epsilon Open Archive (Sveriges lantbruksuniversitet biblioteket (Swedish University of Agricultural Sciences))
Adnyani, N. M. D., Nugraha, I. B. A., Widiana, I. G. R., & Saraswati, M. R. (2020) · Jurnal Penyakit Dalam Udayana · doi:10.36216/jpd.v4i1.128
Williams, J. A. (2021) · doi:10.3998/panc.2021.06
Lighting up targets of dual agonist therapies for diabetes and obesity
(2025) · Nature Metabolism · doi:10.1038/s42255-025-01346-2
The Physiology of Semaglutide in Relation to Glucagon Like Peptide-1: A Comprehensive Review
Barakat, G. M., Hassan, S. E. H., Issa, H., & Ramadan, W. (2025) · Current Drug Therapy · doi:10.2174/0115748855404783250917112146
Murase, S.-I. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04625-7
Clark, M. (2023) · White Rose eTheses Online (University of Leeds, The University of Sheffield, University of York)
De Bray, A. Y. (2025) · Oxford University Research Archive (ORA) (University of Oxford) · doi:10.5287/ora-gpg5vjayz
The Role of Pancreatic Preproglucagon in Regulating Local Inflammation in Mice
Zalucha, E., Hutch, C. R., Bethea, M. M., Cook, T. M., Unadkat, A., Wells, K. L., Kim, K. S., MAERZ, B., Lehrke, M., Singer, K., et al. (2026) · Cells · doi:10.3390/cells15050482
“Whether GLP-1Rs are expressed on macrophages, and other immune cells for that matter, is unknown as commercially available GLP-1R antibodies are not validated and lack specificity [36].”
Ligand‐Dependent Cytotoxicity and Fluorescence Imaging of Coumarin‐based Zinc (II) Complexes
Tran, N. D., Pham, V. T., Nandanwar, S., Doanh, V. V., Nguyen, V. T., Hải, L. T. H., Nguyen, T. M., Nguyen, N. K., Tran, D. L., Kim, H. J., et al. (2026) · ChemistrySelect · doi:10.1002/slct.73731
GLP-1 receptor agonists—a potential therapy for chronic kidney disease?
Boeckhaus, J., Sayer, J. A., & Mabillard, H. R. (2026) · Clinical Science · doi:10.1042/cs20261312
“Whether the renal effects result from direct GLP-1R activation was a topic of discussion [66].”
The incretin-bone axis: molecular mechanisms and clinical implications
Muscarà, A., Bellone, F., & Rossi, M. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1907875
“…confound is antibody speci fi city: numerous commercially available anti-GLP-1r antibodies, including widely used polyclonal reagents, have been shown to generate immunoreactive signal in GLP-1r-knock - out tissue, indicating non-speci fi c binding rather than true receptor detection (28, 29).”
Blontrock, E., Oyaert, M., Ikawaty, R., Cahyono, A., Delrue, C., & Speeckaert, M. M. (2026) · Diagnostics · doi:10.3390/diagnostics16213645
Glucagon-like Peptide-1 Receptor Agonists and Thyroid Cancer: Review of Preclinical and Human Data
Braunstein, E. W., & Braunstein, G. D. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnag044
Hu, W., Song, R., Cheng, R., Liu, C., Guo, R., Tang, W., Zhang, J., Zhao, Q., Li, X., & Liu, J. (2022) · doi:10.3389/fendo.2022.927859.s001
Alsaleh, A. A. (2014) · Otago University Research Archive (University of Otago)
Metadata
- Authors
- Pyke, C., & Knudsen, L. B.
- Affiliations
- Novo Nordisk (Denmark) (DK)
- Corresponding author
- Knudsen, Lotte Bjerre
- Venue
- Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2013-01-01
- Volume
- 154
- Issue
- 1
- Pages
- 4-8
- ISSN
- 0013-7227 (ISSN-L)
- 1945-7170
- OpenAlex
- W2050866589
- Cited by
- 154
- References
- 29
- Citations by year
- 2026: 5 · 2025: 5 · 2024: 4 · 2023: 5 · 2022: 8 · 2021: 10 · 2020: 19 · 2019: 11 · 2018: 6 · 2017: 18 · 2016: 11 · 2015: 19 · 2014: 24 · 2013: 9
- FWCI
- 13.61
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Novo Nordisk
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Keywords
- GLP-1 receptor, GLP-1 receptor agonists, liraglutide, exenatide, DPP-4 inhibitors, macrophages, hepatocytes, receptor localization, type 2 diabetes, atherosclerosis, hepatic steatosis, G protein-coupled receptors
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Animals, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Receptors, Glucagon, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.